| RRC ID |
69774
|
| Author |
Inoue M, Horiuchi K, Susa M, Taguchi E, Ishizaka T, Rikitake H, Matsuhashi Y, Chiba K.
|
| Title |
Trabectedin suppresses osteosarcoma pulmonary metastasis in a mouse tumor xenograft model.
|
| Journal |
J Orthop Res
|
| Abstract |
Osteosarcoma (OS) is the most common primary bone tumor that mainly affects adolescents and young adults. Although standard treatment modality can achieve up to 60%-70% 5-year survival rate, there has not been any substantial improvement over the past four decades. Furthermore, those presenting with pulmonary metastatic lesions often undergo a highly unfavorable clinical course. Therefore, there is a severely unmet clinical need to provide a more effective treatment for patients with OS. In this study, we show that trabectedin (TBD), a chemotherapeutic agent approved for soft tissue sarcomas, significantly suppresses pulmonary metastasis in a mouse OS xenograft model. In vitro experiments revealed that TBD suppresses cell migration potentially by downregulating the activity of ERK1/2, intracellular molecules that are critically involved in the regulation of cell motility. Collectively, our data may provide a basis for further investigation of TBD on the potential use for OS patients who are at great risk of pulmonary metastasis.
|
| Volume |
40(4)
|
| Pages |
945-953
|
| Published |
2022-4-1
|
| DOI |
10.1002/jor.25105
|
| PMID |
34057747
|
| MeSH |
Adolescent
Animals
Bone Neoplasms* / drug therapy
Bone Neoplasms* / pathology
Cell Line, Tumor
Cell Movement
Cell Proliferation
Disease Models, Animal
Heterografts
Humans
Lung Neoplasms* / pathology
Mice
Neoplasm Metastasis
Osteosarcoma* / drug therapy
Osteosarcoma* / pathology
Trabectedin / therapeutic use
|
| IF |
2.728
|
| Resource |
| Human and Animal Cells |
LM8(RCB1450) |
